^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
Published date:
09/01/2023
Excerpt:
We further demonstrate that lurbinectedin, either as a single agent or in combination with osimertinib, causes an appreciable antitumor response in multiple models of EGFR-mutant lung adenocarcinoma...
DOI:
https://doi.org/10.1158/1078-0432.CCR-23-0471
